TWST: What are the messages you wish to convey to them?
Mr. Koly: This company is for real. It is tremendously undervalued at
the moment, with a valuation in the $20-million range. This is very low
for a company in a Phase III human clinical pivotal study for a
technology that, potentially, will address a deadly disease for which
there is currently no effective treatment. We are not claiming to have a
cure for cancer, but we are claiming that, with this drug delivery
system, we can extend life for many of these patients. We intend to
prove that through our clinical studies. The Delcath system may offer a
very substantial improvement in the quality of life of cancer patients
who are undergoing chemotherapy treatment, including a significant
reduction in side effects.